The Innovation Awards 2017
Total Page:16
File Type:pdf, Size:1020Kb
DECEMBER 2017 # 36 Upfront In My View NextGen Sitting Down With Continuous processing Why Brexit is a concern for Lending a helping hand to Richard Markus, Amgen meets cell therapies academic research specialty vaccines biosimilar champion 12 18 – 19 40 – 42 50 – 51 The Innovation Awards 2017 What is the most innovative technology to hit the pharma manufacturing market this year? 22 – 31 www.themedicinemaker.com | Active ingredients Dynamic people What do you need from your API partner? Custom development and manufacturing or generic expertise? Safety, quality and reliability? Excellent. You’ll enjoy working with Cambrex. www.cambrex.com Jesper Kumlin Process Operator Production The Medicine Maker_266_210.indd 4 16/08/2016 12:25 Online this Month 2017 Highlights Pharma’s Green Rush Exploring Pharma’s Far Future June 2017 November 2017 Global Vigilance Medical cannabis may be Delving into the possibilities of February 2017 controversial, but there could be healthcare and medicine a century Following the heparin tragedy, other ways that pharma can make from now throws up interesting something needed to be done in terms use of the cannabis plant; certain questions. Will we end up in a utopian of global safety. Rx-360 was created to cannabinoids may be useful sources or dystopian era of health? help improve supply chains. for new drug discovery. http://bit.ly/2nOSqh3 http://bit.ly/2l8gbi2 http://bit.ly/2hKQtPT The Power List 2017 Heal the World April 2017 August 2017 The best and brightest of the industry There’s a large philanthropic side to are highlighted in our celebration of pharma that’s often overshadowed the 100 most influential people in by negative press. Here, we show the drug development. effect corporate social responsibility http://bit.ly/2qVocVY has on the world. http://bit.ly/2fLqGq6 Delivering on a Promise May 2017 Twenty-First Century Cell Therapy Drug delivery approaches have September 2017 been growing in complexity. This Following the first FDA-approved article highlights the advanced T cell therapy this year, all eyes have techniques being developed for future been on the field of cell and gene therapeutics. therapy – an area full of promise, and http://bit.ly/2knr2Bt possible pitfalls. http://bit.ly/2C64LAw And Coming Up in 2018... Nominations Closing for the 2018 Power List The Medicine Maker 2018 Power List will be published in April – and nominations will draw to a close on February 1. The list celebrates 100 prominent and inspirational individuals involved in drug development and manufacture across four categories: Masters of the Bench, Industry Influencers, Business Captains, and Champions of Change. Who will be included on the list? It’s up to you to decide – just fill out the quick nomination form to tell us who you want to see on the list: http://tmm.txp.to/2018/powerlist We accept nominations from all corners of the industry and for individuals in all roles – from top CEOs, down to unsung heroes making a mark in R&D or process development. www.themedicinemaker.com Power List 2017 ISSUE 36 - DECEMBER 2017 Contents Editor - Stephanie Sutton [email protected] Associate Editor - James Strachan [email protected] Parenteral drug Associate Editor - William Aryitey [email protected] Content Director - Rich Whitworth [email protected] Editorial Director - Fedra Pavlou development services [email protected] Publisher - Richard Hodson [email protected] Sales Manager - Helen Conyngham [email protected] We make drugs smarter. Head of Design - Marc Bird [email protected] Junior Designer - Hannah Ennis [email protected] Digital Team Lead - David Roberts [email protected] Digital Producer Web/Email - Peter Bartley Brookwood Evonik Transferra [email protected] Digital Producer Web/App - Abygail Bradley Pharmaceutical Services™ Nanosciences® [email protected] Audience Insight Manager - Tracey Nicholls z feasibility studies, process z leader in lipid nanoparticle [email protected] development, scale-up & (LNP) drug delivery Traffic & Audience Database Coordinator - Hayley Atiz commercial manu- [email protected] facturing of extended z targeting & stabilizing Traffic and Audience Associate - Lindsey Vickers [email protected] release formulations for oligonucleotide drugs Traffic and Audience Manager - Jody Fryett local & systemic delivery [email protected] z solubility & bioavailability Social Media / Analytics Associate - Ben Holah [email protected] z microparticles, enhancement of HPAPIs Events Manager - Alice Daniels-Wright nano particles, implants, [email protected] liposomes, nano- z LIPEX® extruders for Marketing Manager - Katy Pearson [email protected] medicines, conjugates benchtop to commercial Financial Controller - Phil Dale production of LPNs [email protected] z formulations with small Accounts Assistant - Kerri Benson [email protected] molecules, peptides, Chief Executive Officer - Andy Davies proteins, nucleic acids, [email protected] vaccines, HPAPIs, Chief Operating Officer - Tracey Peers controlled substances [email protected] Change of address: [email protected] Hayley Atiz, The Medicine Maker, evonik.com/parenterals Texere Publishing Ltd, Haig House, Haig 12 Road, Knutsford, Cheshire, WA16 8DX, UK [email protected] General enquiries: www.texerepublishing.com [email protected] +44 (0) 1565 745200 [email protected] 03 Distribution: Online This Month Upfront The Medicine Maker (ISSN 2055-8201), and The Medicine Maker North America (ISSN 2514-7536), is published monthly by 10 Flu Fighters Texere Publishing Ltd and is distributed in 09 the US by UKP Worldwide, 3390 Rand Road, Editorial South Plainfield, NJ 07080 Wise Words, by Stephanie Sutton 11 S pray it Again, Sam Periodicals postage paid at South Plainfield, NJ POSTMASTER: Send US address changes to The Medicine Maker C/O 3390 Rand Road, South Plainfield NJ 07080. 12 Continuing the Trend Single copy sales £15 (plus postage, cost available on request [email protected]) On The Cover Annual subscription for non-qualified DECEMBER 2017 # 36 14 Sharing is Caring recipients £110 Upfront In My View NextGen Sitting Down With Continuous processing Why Brexit is a concern for Lending a helping hand to Richard Markus, meets cell therapies academic research specialty vaccines Amgen 08 – 09 16 – 17 40 – 42 50 – 51 Celebrating the technology stars Reprints & Permissions – [email protected] The opinions presented within this publication are those of the authors of 2017 with the annual and do not reflect the opinions of The Medicine Maker or its publishers, Texere Publishing. Authors are required to disclose any relevant financial The Innovation Awards 2017 Innovation Awards arrangements, which are presented at the end of each article, where relevant. What is the most innovative technology to hit the pharma market this year? 20 – 29 www.themedicinemaker.com © 2017 Texere Publishing Limited. All rights reserved. Reproduction in whole or in parts is prohibited. 17-01-392 AZ, parenteral drug delivery, 266x210mm.indd 1 14.11.17 09:28 Parenteral drug development services We make drugs smarter. Brookwood Evonik Transferra Pharmaceutical Services™ Nanosciences® z feasibility studies, process z leader in lipid nanoparticle development, scale-up & (LNP) drug delivery commercial manu- facturing of extended z targeting & stabilizing release formulations for oligonucleotide drugs local & systemic delivery z solubility & bioavailability z microparticles, enhancement of HPAPIs nano particles, implants, liposomes, nano- z LIPEX® extruders for medicines, conjugates benchtop to commercial production of LPNs z formulations with small molecules, peptides, proteins, nucleic acids, vaccines, HPAPIs, controlled substances evonik.com/parenterals [email protected] 17-01-392 AZ, parenteral drug delivery, 266x210mm.indd 1 14.11.17 09:28 PERFECT FUSION Your Molecule + Optimized Media Introducing EX-CELL® Advanced™ HD Perfusion Medium. The first off-the-shelf high-density cell culture medium available for continuous processing. It’s never been easier to be more productive. Learn More sigmaaldrich.com/perfusion The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. In My View PERFECT 50 16 How do we tackle metabolism- based causes of drug attrition? 44 FUSION asks Guy Weber. 17 Bioprinting could revolutionize Reports Your Molecule + Optimized Media drug development and testing, Introducing EX-CELL® Advanced™ HD Perfusion says Erik Gatenholm. NextGen 15 How to Cultivate a Medium. The first off-the-shelf high-density cell Quality Mindset culture medium available for continuous processing. 18 Steve Marginn is concerned 40 Fantastic Vaccines and Where about the impact of Brexit on to Find Them: Lessons Learned 20 The Problem with Poloxamers It’s never been easier to be more productive. UK academic research. with Nima Farzan The CEO of PaxVax talks us 32 The Innovators Learn More through the challenges – and sigmaaldrich.com/perfusion opportunities – that lie within 48 The Transformation Feature the specialty vaccine field. to Excellence 22 The 2017 Innovation Awards 44 Th e Best Defense Is Which new